October 5, 2005 -- Although LymphoSta-B failed to provide a benefit in a Phase II lupus trial, Human Genome Sciences stressed that the drug was effective among 75% of the population, OXiGene said its vascular disrupting agent provided a benefit to lung cancer patients, AlgoRx and Corgentech announced positive Phase III results from their fast-onset needleless anesthetic, Pfizer received FDA approval for Aromaxin as a partial replacement to tamoxifen in breast cancer, ZymoGenetics received Orphan Drug status for its melanoma drug, Jubilant Organosys of India bought US-based Target Research Associates, a clinical research organization, for $35.5 million. In its biggest recent setback, the Centient Biotech 200 lost 81 points to close at 3705, a drop of 2.15%. More details...
